CL-82198-DataSheet-生命科學試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemECL-82198Cat.No.:HY-100359CASNo.:307002-71-7分?式:C??H??N?O?分?量:302.37作?靶點:MMP作?通路:MetabolicEnzyme/Protease儲存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實驗DMSO:100mg/mL(330.72mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲備液1mM3.3072mL16.5360mL33.0721mL5mM0.6614mL3.3072mL6.6144mL10mM0.3307mL1.6536mL3.3072mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；?旦配成溶液，請分裝保存，避免反復凍融造成的產(chǎn)品失效。儲備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲存時，請在6個?內(nèi)使?，-20°C儲存時，請在1個?內(nèi)使?。體內(nèi)實驗請根據(jù)您的實驗動物和給藥?式選擇適當?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液，再依次添加助溶劑：(為保證實驗結果的可靠性，澄的儲備液可以根據(jù)儲存條件，適當保存；體內(nèi)實驗的?作液，建議您現(xiàn)?現(xiàn)配，當天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.5mg/mL(8.27mM);Clearsolution1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE2.請依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.5mg/mL(8.27mM);Clearsolution3.請依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥2.5mg/mL(8.27mM);ClearsolutionBIOLOGICALACTIVITY?物活性CL-82198?個選擇性的MMP-13抑制劑。CL-82198與MMP-13的整個S1'?袋結合，這其對MMP-13選擇性和對其他MMP缺乏抑制活性的礎。CL-82198可?于?關節(jié)炎(OA)的研究。體外研究CL-82198(10μM;24hours)significantlyreducesLS174cellmigration[1].CL-82198decreasesCTGFandTGF-β1proteinlevelsinhepaticstellatecells[3].體內(nèi)研究CL82198(1-10mg/kg;i.p.;everyotherdayfor12weeks)preventsanddeceleratesMLI-inducedosteoarthritisprogression[4].AnimalModel:10-week-oldC57BL/6Jmice(performedMLIsurgery)[4]Dosage:1,5,10mg/kgbodyweightAdministration:Intraperitonealinjection;everyotherdayfor12weeksResult:PreventedanddeceleratedMLI-inducedosteoarthritisprogression.戶使?本產(chǎn)品發(fā)表的科研?獻?NatCommun.2022Jul11;13(1):4007.?JCellPhysiol.2019Sep;234(9):15395-15406.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].RathTetal.Matrixmetalloproteinase-13isregulatedbytoll-likereceptor-9incolorectalcancercellsandmediatescellularmigration.OncolLett.2011May;2(3):483-488.[2].WohlauerMetal.Nebulizedhypertonicsalineattenuatesacutelunginjuryfollowingtraumaandhemorrhagicshockviainhibitionofmatrixmetalloproteinase-13.CritCareMed.2012Sep;40(9):2647-53.[3].GeorgeJ,etal.MMP-13deletiondecreasesprofibrogenicmoleculesandattenuatesN-nitrosodimethylamine-inducedliverinjuryandfibrosisinmice.JCellMolMed.2017Dec;21(12):3821-3835.[4].WangM,etal.MMP13isacriticaltargetgeneduringtheprogressionofosteoarthritis.ArthritisResTher.2013Jan8;15(1):R5.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalappli